Drug Search Results
More Filters [+]

Semaxanib

Alternative Names: semaxanib, su5416
Latest Update: 2023-09-22
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: VEGFR2 Inhibitor,AhR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Semaxanib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Colorectal Cancer

Phase 2: Cervical Cancer|Melanoma|Colorectal Cancer|Renal Cell Carcinoma|Kidney Cancer|Uterine Cancer|Glioma|Sarcoma|Plasmacytoma|Multiple Myeloma|Astrocytoma|Gastrointestinal Stromal Tumors|Brain Stem Cancer|HIV Infections|Sarcoma, Kaposi|Preleukemia|Juvenile Myelomonocytic Leukemia,|Anemia, Refractory, with Excess of Blasts|Acute Monocytic Leukemia|Anemia, Aplastic|Mesothelioma|Adenocarcinoma|Head and Neck Cancer|Myelodysplastic Syndrome|Skin Cancer|Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Squamous Cell Carcinoma|Acute Myelomonocytic Leukemia|Prostate Cancer|Chronic Myeloid Leukemia

Phase 1: Vascular Cancer|Oncology Solid Tumor Unspecified|Inflammatory Breast Cancer|Peritoneal Cancer|Fallopian Tube Cancer|Ovarian Cancer|Head and Neck Cancer|Sarcoma, Kaposi|Brain Stem Cancer|Prostate Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SUGEN-SU5416.031

P3

Completed

Colorectal Cancer

2007-09-01

NCI-2012-02345

P2

Terminated

Colorectal Cancer

2007-02-01

U01CA062505

P2

Completed

Renal Cell Carcinoma|Kidney Cancer

2007-02-01

NCI-2012-02351

P2

Completed

Mesothelioma

2007-02-01

Recent News Events